Dr. Amie Phinney reports

DEFENCE THERAPEUTICS EXPANDS RADIOPHARMACEUTICAL DEVELOPMENT STRATEGY WITH ALPHA AND BETA-EMITTER PROGRAMS

Defence Therapeutics Inc. has expanded its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. This expansion is to broaden the capability of the Accum platform, which is designed to facilitate intracellular transport for enhanced payload delivery.

The initiative reflects Defence's growing strategic focus on radiopharmaceuticals, a rapidly advancing area of precision oncology where the company believes Accum has significant potential to create novel products and improve existing ones. Accum improves how well radioactive drugs get inside cancer cells, allowing more of the cancer-killing payload to reach its target and destroy the tumour from within. Defence is accelerating the development of its internal radiopharmaceutical program to further evaluate this potential and advance Accum-enabled radio-immunoconjugates candidates toward clinical development.

Defence's radiopharmaceuticals program will evaluate alpha emitters, such as actinium-225, for their high-energy, short-range localized cellular damage. Concurrently, the company will evaluate beta emitters, such as lutetium-177, for their medium-energy, longer-range penetration profiles, allowing for a comprehensive comparison of how different isotope properties are enhanced by the Accum platform.

The expanded program is designed to generate comparative pharmacology, efficacy and safety data across both isotope classes while further establishing Accum as a versatile intracellular delivery platform for a variety of radioisotope payloads. The continuing preclinical programs are focused on the Accum platform's core mechanism to optimize accumulation in target cells and reduce off-target toxicity. By building out the preclinical data, Defence aims to deliver clinical candidates and strengthen the company's growing pipeline of proprietary radiopharmaceutical assets.

"By expanding our platform development to evaluate both alpha and beta isotopes as distinct pathways, we can comprehensively analyze the compatibility of Accum with different payload profiles," said Dr. Ryan Simms, Defence's newly instated chief operating officer and head of radiopharmaceuticals program.

"This parallel development program gives Defence the data required to optimize Accum-enhanced radio-immunoconjugates for diverse candidate selections and to establish Accum as a technology capable of enhancing the next generation of targeted therapies across multiple therapeutic modalities," said Dr. Amie Phinney, president and chief executive officer of Defence Therapeutics.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursuing cutting-edge science and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most.

We seek Safe Harbor.